In COVID-19 clinical update #123, Dr. Griffin discusses rapid diagnostic testing in response to the monkeypox outbreak, leading causes of death in the US during the COVID-19 pandemic, antibody evasion by subvariants, broadly-neutralizing antibodies against emerging variants, factors associated with severe outcomes among hospitalized immunocompromised adults, measurement of the burden of hospitalizations during the pandemic, parental vaccine hesitancy in diverse communities, evaluating saliva sampling to improve access to diagnosis in low-resource settings, oral sabizabulin for high-risk hospitalized adults, lower-risk of multisystem inflammatory syndrome in children, and neurovascular injury with complement activation and inflammation during infection.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Monkeypox outbreak rapid testing response (CDC)
• Leading causes of death during pandemic (JAMA)
• FDA recommends vaccine update (FDA)
• Antibody evasion by subvariants (Nature)
• Broadly-Neutralizing antibodies against variants (Frontiers in Immunology)
• Severe outcomes factors in immunocompromised adults (CDC)
• Measurement of the burden of hospitalizations (OFID)
• Vaccine hesitancy among parents (Academic Pediatrics) 
• PAXLOVID patient eligibility screening checklist (FDA)
• Remdesivir fact sheet for providers (Veklury) 
• Bebtelovimab fact sheet for providers (FDA)
• Saliva evaluation to improve diagnostics (ASTMH)
• Oral Sabizabulin for high-risk adults (NEJM)
• Lower risk of MIS-C in children (CID)
• Neurovascular injury during infection (Brain)
• Paul Offit on TWiV 917
• Contribute to FIMRC fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 918
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]